Novo Nordisk, the maker of weight-loss drug Wegovy, announced its quarterly results. Adjusted operating profit for 1Q26 amounted to 32.86 billion Danish kroner (USD5.16 billion), down 15% YoY, or down 6% YoY at constant exchange rates, above market expectations of 28.74 billion Danish kroner. Quarterly net sales rose 24% YoY to 96.823 billion Danish kroner, or up 32% YoY at constant exchange rates.The company expects full-year adjusted sales and operating profit to decline by 4% to 12% at constant exchange rates, compared with its previous forecast range of a 5% to 13% decline. CEO Mike Doustdar said in a statement that the strong performance of Wegovy, coupled with continued growth in international operations, prompted the company to raise its related guidance.Related NewsEIA Crude Oil Stocks Change for May/08 in the United States is -4.306M, lower than the previous value of -2.313M. The forecast was -2.10M.Novo Nordisk had enjoyed a window as the only oral weight-loss drug provider in the US market, but this period ended early last month after a competing drug, Foundayo, developed by Eli Lilly and Company (LLY.US) , received approval from the US Food and Drug Administration. Eli Lilly and Company also raised its full-year earnings and revenue forecasts last week. (fc/w)(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
AASTOCKS Financial News